Inventor
ZOU GE
US14 patents
⚠️ This page may combine multiple inventors who share the name “ZOU GE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
INCYTE CORP
7 patentsUS10065963B2Sep 4, 2018
Heterocyclic compounds as PI3K-γ inhibitors
INCYTE CORP16 citations92
US10472368B2Nov 12, 2019
Heterocyclic compounds as PI3K-γ inhibitors
INCYTE CORP12 citations84
US10596184B2Mar 24, 2020
Aza-heteroaryl compounds as PI3K-gamma inhibitors
INCYTE CORP6 citations83
US10022387B2Jul 17, 2018
Aza-heteroaryl compounds as PI3K-gamma inhibitors
INCYTE CORP15 citations83
US9586949B2Mar 7, 2017
Aza-heteroaryl compounds as PI3K-gamma inhibitors
INCYTE CORP14 citations83
US11091491B2Aug 17, 2021
Heterocyclic compounds as PI3K-y inhibitors
INCYTE CORP4 citations73
US11773102B2Oct 3, 2023
Heterocyclic compounds as PI3K-γ inhibitors
INCYTE CORP0 citations62
HOFFMANN LA ROCHE
7 patentsUS12503471B2Dec 23, 2025
Triazatricycle compounds for the treatment of autoimmune disease
HOFFMANN LA ROCHE0 citations62
US12486273B2Dec 2, 2025
Hydro-1H-pyrrolo[1,2-a]pyrazine compounds for the treatment of autoimmune disease
HOFFMANN LA ROCHE0 citations62
US12421240B2Sep 23, 2025
Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
HOFFMANN LA ROCHE0 citations62
US11639352B2May 2, 2023
Benzothiazole compounds for the treatment of autoimmune diseases
HOFFMANN LA ROCHE0 citations62
US11548884B2Jan 10, 2023
Cyclic amidine compounds for the treatment of autoimmune disease
HOFFMANN LA ROCHE0 citations61
US12157746B2Dec 3, 2024
Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
HOFFMANN LA ROCHE0 citations52
US11952363B2Apr 9, 2024
Piperazine compounds for the treatment of autoimmune disease
HOFFMANN LA ROCHE0 citations50